AIM Breakfasts

AIM BREAKFAST – 27th January 2017

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 972

Total number of AIM Companies trading: 950*
* As at 20 January 2017

Dish of the Day:

No AIM Joiners Today

 

Off the Menu:

No AIM Leavers Today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): 85*

Total number of ISDX Growth Market Companies trading: 81*
* As at 20 January 2017

Dish of the Day:

No NEX Growth Market Joiners Today

Off the Menu:

No NEX Growth Market Leavers Today

What’s Cooking in the IPO Kitchen?

Rainbow Rare Earths has published a prospectus. It has raised $8m to  fast-track fully permitted  high grade Gakara ‘rare earths’ project  to production  in Burundi. Intends to join the Standard List of the LSE.

Impact healthcare REIT— Intends to float on the main market. Seeks to raise £160m to acquire a portfolio of up to 58 care homes. Expected Admission 7 March.

Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.

 

Breakfast Buffet

Formation Group (NEX:FRM) 1.85p £4.1m

FYAug16 results from the property development and project management  Company. Group revenue growth of 24% to GBP29.410m (2015: GBP23.764m) on the back of an increasing workload driven by the current strong London property market. Profits before taxation of GBP2.157m from continuing operations (2015 profit:     GBP2.203m). Formation Group continues to be positive that its core property construction activity remains strong and that it will be able to continue to generate substantial revenues. The Group continues to have a healthy on-going project stream that  will include the final sales of the Iverson Road apartments, expected to occur during the year ending 31 August 2017.

 

Omega Diagnostics (ODX.L) 17.5p £19.03m

The medical diagnostics Company focused on allergy, food intolerance and infectious disease, announced an update on its discussions with Immunodiagnostic Systems Holdings. The preferred course of action is to pursue an enlarged distribution relationship with the Company. Currently, IDS has contractual rights to be appointed as the Company’s exclusive distributor in territories comprising the UK, France, Germany, Austria, Switzerland, Nordic countries and the United States of America. The ongoing discussions will therefore focus on how Omega can attain a more global reach for its Allersys® range of allergy tests in a structure that benefits both organisations.  Currently, the Company has 41 CE-Marked allergy tests which can be run on the IDS iSYS automated instrument.

 

Ubisense Group (UBI.L) 42p £23.47m

FY Dec16 trading statement from the specialist in high performance Enterprise Location Intelligence systems, through its RTLS and mobility focused geospatial (myWorld) offering. The Company showed continued good progress in terms of revenue growth, margins, cost management and order book, all of which are significantly better than those achieved in 2015. The increased focus on the RTLS software platform has paid off with the signing of a global software licence deal with a major automotive manufacturer. “We also signed some significant new and extended RTLS product orders. In the geospatial division, we are seeing increased demand for myWorld services projects and new licence sales.” Ended year with net cash position which improved in January through  debtor collections, and is in compliance with new HSBC facility. banking covenants.

 

Mortgage Advice Bureau(MAB1.L) 372.5p £187.97m

One of the UK’s leading networks for mortgage intermediaries, has issued a pre-close trading update for the year ended 31 December 2016. revenues. In line with market consensus revenue increased by 23% to £92m driven by a 23% increase in the average number of Advisers to 888 with 950 at the period end. Although average revenue per adviser was flat in 2016 due to the impact of the lull in activity in the housing and mortgage market surrounding the EU referendum, MAB expects to see growth in the current year. Underlying profit before tax for the year ended 31 December 2016 was ahead of market consensus despite the impact of this lull. MAB is focussed on growing market share. FY17E rev of £109.9mand PBT of £14.23m

 

CEPS (CEPS.L) 37p £3.5m

CEPS has raised £1.27m in a placing at 35p with  institutional and private investors and certain related parties. The net proceeds of the Placing will be used to repay the third party loan of £690,000 that was entered into at the time of the Company’s acquisition of Hickton Holdings Limited as set out in the Company’s announcement dated 1 February 2016, and for general working capital purposes.  Hickton supplies “clerk of works” services to the construction industry.

 

Dorcaster (DAR.L) 162.5p £16.25m

Dorcaster announced that it has extended the period of exclusivity granted by the exclusivity agreement entered into with the shareholders of Escape Hunt to 31 March 2017 in order to allow the Company to complete the due diligence and associated funding. As a result the Company has requested that the suspension of trading in its shares remain until such time that: it has published an admission document for the group as it would be enlarged following the proposed acquisition; negotiations in relation to the proposed acquisition have been terminated; or the period of exclusivity granted to the Company has expired.

 

Coral Products (CRU.L) 12p £9.91m

Following a poor trading performance at its Coral Products Mouldings Limited subsidiary during November and December 2016, group profitability for the year ending 30 April 2017 is likely to be materially below management’s and market expectations. Immediate steps have been taken to improve performance at Mouldings and losses are expected to be reduced from January  onwards although a loss is forecast for the financial year. The Board also announces that for personal reasons, Mr Roberto Zandona, CEO, has resigned. Furthermore, Stephen Fletcher, Finance Director  has retired also for personal reasons. Joe Grimmond moves to Exec Chair. Overall Coral remains profitable, cash generative and with a strong asset base.

 

Porta Communications(PTCM.L) 4p £12.38m

The international communications and marketing group has agreed the settlement of a debt of £530,247 due to Retro Grand Limited (managed and administered by a corporate trustee, Morton PTC Limited) by way of the allotment and issue of 12,476,389 shares.  The Debt Conversion constitutes a related party transaction pursuant to Rule 13 of the AIM Rules as Morton PTC Limited is the owner of Hawk Investment Holdings Limited (a substantial shareholder of the Company) as the trustee of the Morton Family Trust, and Retro Grand as the trustee of the Edward Trust.

 

Condor Gold (CNR.L) 56p £29.63m

Condor Gold announced, further to the announcement of 15 December 2016, the scout drilling results for four drill holes totalling 719.6 m on the Cacao Prospect at the La India Project. This drilling is designed to test targets with the potential to contribute to La India’s high grade mineral resource of 18 Mt at 4.0 g/t for 2.31 Moz gold. Drill core demonstrates a significant dilational vein at Cacao, with the prospect of a much larger gold resource.   Cacao forms a major “Link” between two major basement feeder zones (La India and Andrea Corridors). Drill intercepts: 7.85 m at 3.75 g/t gold, 7.85 m at 2.95 g/t gold and 17.1 m at 1.74 g/t gold, demonstrate broad zones of gold mineralisation.

 

RTC Group (RTC.L) 43.5p £6.33m

FY Dec 16 trading update. “We are pleased that our trading is in line with market expectations.  All of our group businesses had a strong end to the year and we remain confident that this positive momentum will continue in 2017.” RTC has three principal trading subsidiaries engaged in the recruitment of human capital resources and the provision of managed services. FYDec16E rev £68m and PBT of £1.1m.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.